Document Detail


Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
MedLine Citation:
PMID:  1967562     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A new cardioselective beta 1-adrenergic receptor agonist xamoterol (Corwin) has been developed for the treatment of heart failure. To study the acute hemodynamic effects of xamoterol, 24 patients, 39-70 years old, with mild-to-moderate postinfarction left ventricular dysfunction entered a double-blind, between-patient comparison of a single 5-minute intravenous infusion of xamoterol (0.2 mg/kg) and placebo. The acute hemodynamic effects of xamoterol were measured at rest and during two multistaged symptom-limited supine bicycle exercise tests (Ex-T), a control Ex-T followed by an Ex-T with either xamoterol or placebo. Compared with placebo, xamoterol significantly increased left ventricular contractility (Vmax and positive [+] dP/dt) and enhanced relaxation (dP/dt- and time constant relaxation) at rest and at the 25% and 50% levels of maximum exercise. The heart rate, the frequency and time to onset of anginal symptoms, the magnitude of exercise-induced ST segment depression, the left ventricular end-diastolic and peak systolic pressures, the mean pulmonary artery pressures, the cardiac index, the left ventricular stroke-work index, and the epinephrine and norepinephrine plasma levels at rest and during exercise did not differ significantly between placebo xamoterol groups. Thus, xamoterol can be a useful addition for the treatment of left ventricular dysfunction because of long-term ischemic heart disease.
Authors:
P J de Feyter; P W Serruys; H Suryapranata
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Circulation     Volume:  81     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1990 Feb 
Date Detail:
Created Date:  1990-03-13     Completed Date:  1990-03-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  III99-106     Citation Subset:  AIM; IM    
Affiliation:
Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / therapeutic use*
Angina Pectoris / drug therapy*
Double-Blind Method
Exercise / physiology
Exercise Test
Humans
Male
Middle Aged
Myocardial Contraction / drug effects*
Myocardial Infarction / drug therapy*
Propanolamines / therapeutic use*
Randomized Controlled Trials as Topic
Xamoterol
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Propanolamines; 81801-12-9/Xamoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart fai...
Next Document:  Morphometrical and microdensitometrical studies on peptide- and tyrosine hydroxylase-like immunoreac...